openheart Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy

Marijke Wasielewski,¹ Karin Y van Spaendonck-Zwarts,^{1,2} Nico-Derk L Westerink,¹ Jan D H Jongbloed,¹ Aleida Postma,³ Jourik A Gietema,⁴ J Peter van Tintelen,¹ Maarten P van den Berg⁵

To cite: Wasielewski M, van Spaendonck-Zwarts KY, Westerink N-DL, *et al.* Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. *Open Heart* 2014;1:e000116. doi:10.1136/openhrt-2014-000116

MW and KYvS-Z contributed equally.

Received 3 March 2014
Revised 15 May 2014
Accepted 24 May 2014

ABSTRACT

Objective: Anthracyclines are successfully used in cancer treatment, but their use is limited by their cardiotoxic side effects. Several risk factors for anthracycline-associated cardiomyopathy (AACM) are known, yet the occurrence of AACM in the absence of these known risk factors suggests that other factors must play a role. The purpose of this study was to evaluate whether a genetic predisposition for dilated cardiomyopathy (DCM) could be a potential risk factor for AACM.

Methods: A hospital-based registry of 162 DCM families and two hospital-based registries of patients with cancer treated with systemic cancer therapy (n>6000) were reviewed focusing on AACM. Selected patients with AACM/DCM families with possible AACM (n=21) were analysed for mutations in cardiomyopathy-associated genes and presymptomatic cardiological evaluation of first-degree relatives was performed.

Results: We identified five DCM families with AACM and one patient with AACM with a family member with a possible early sign of mild DCM. Pathogenic *MYH7* mutations were identified in two of these six families. The *MYH7* c.1633G>A (p.Asp545Asn) and c.2863G>A (p.Asp955Asn) mutations (one double mutant allele) were identified in a DCM family with AACM. The *MYH7* c.4125T>A (p.Tyr1375X) mutation was identified in one patient with AACM.

Conclusions: This study further extends the hypothesis that a genetic predisposition to DCM could be a potential risk factor for AACM.

INTRODUCTION

Anthracyclines, such as doxorubicin, epirubicin and daunorubicin, are important drugs in the treatment of cancer. Their use in clinical practice is hampered by their cardiotoxic side effects.^{1–3} These effects are variable and range from transient electrophysiological abnormalities to anthracycline-associated cardiomyopathy (AACM) and heart failure.^{1–4} AACM typically presents as left ventricular (LV) dysfunction/dilated cardiomyopathy (DCM) in adults. In children, AACM may also present as restrictive cardiomyopathy.^{4–5}

KEY MESSAGES

What is already known about this subject?

- ▶ Anthracyclines can cause anthracycline-associated cardiomyopathy (AACM). Several risk factors for AACM are known. However, other risk factors must exist as AACM also occurs in the absence of these risk factors.

How might this impact on clinical practice?

- ▶ The results of our study provide further support for the hypothesis that a genetic predisposition for familial dilated cardiomyopathy (DCM) could be a potential risk factor for anthracycline-associated cardiomyopathy (AACM). Although more research is needed, our preliminary results should alert clinicians to the possibility of AACM if a patient reports a personal and/or familial history of DCM/heart failure. Conversely, if a patient with cancer develops disproportional LV dysfunction after anthracycline treatment, one could consider offering the index patient DNA analysis of cardiomyopathy-associated genes and presymptomatic cardiological evaluation to first-degree family members.

What does this study add?

- ▶ In patients with cancer with a family history of dilated cardiomyopathy (DCM)/heart failure, one should be vigilant for increased susceptibility to anthracycline-associated cardiomyopathy (AACM) and one may consider more intensive cardiovascular monitoring before and during cancer treatment or alternative non-cardiotoxic cancer therapy.
- ▶ Identifying a cardiomyopathy-related mutation facilitates genetic cascade screening in family members, which can be helpful in identifying individuals at risk (and in dismissing relatives who do not carry the mutation from regular cardiac monitoring). This enables timely diagnosis to be made, with the possibility of preventing complications and reducing morbidity and mortality.

AACM may become apparent during anthracycline therapy, or within the first year thereafter, or later (sometimes even 10–20 years

For numbered affiliations see end of article.

Correspondence to

Dr Karin Y van Spaendonck-Zwarts;
k.y.vanspaendonck@amc.nl

after treatment).^{4 6} It has been suggested that anthracyclines cause cardiac dysfunction through myocyte damage due to excess production of reactive oxygen species.^{7 8} However, other mechanisms, such as anthracycline-dependent inhibition of topoisomerase II β and selective inhibition of cardiomyocyte-specific gene expression, have also been proposed.^{7 9} The risk of AACM depends on the cumulative dose of administered anthracyclines.^{1 2} In adults, the recommended maximum cumulative doses of doxorubicin and epirubicin are (in general) 550 and 900 mg/m², respectively.¹⁰ In children, the maximum cumulative dose of anthracyclines is (in general) 450 mg/m².¹¹ Additional risk factors for AACM have been identified, including both a younger age as well as an older age at treatment, female gender, mediastinal radiation and pre-existing heart disease.^{1 2 12} Yet, the occurrence of AACM in the absence of these known risk factors suggests that other predisposing factors must play a role.

Recently, we reported two patients with AACM with multiple family members diagnosed with DCM, suggesting the presence of a genetic predisposition for DCM in these families.¹³ In one of these families, we confirmed this finding by identifying a double mutant *MYH7* allele. Based on these observations we hypothesise that a genetic/familial predisposition for DCM might be a potential risk factor for AACM.

To further corroborate the concept that a genetic/familial predisposition for DCM might be a potential risk factor for AACM, we have searched for patients with AACM in our registry of DCM families and, reciprocally, searched for the presence of familial cardiomyopathy in patients with AACM among two registries of patients with cancer treated with systemic therapy.

METHODS

Patients and clinical evaluation

Patients with AACM were selected from our hospital-based registry of proven DCM families (cohort I¹⁴) and from two hospital-based registries of patients with cancer (adult or childhood onset) treated with systemic therapy (cohort II—adult onset patients, cohort III—childhood onset patients¹⁵). For the flow chart of patient inclusion, see figure 1. All participants seen at our cardiogenetics outpatient clinic underwent a counselling procedure and agreed to take part in our study. The institutional review committee approved the protocol.

Cohort I: Hospital-based registry of DCM families

Patients with idiopathic DCM (and other putative inherited cardiac disorders) are routinely evaluated at the cardiogenetics outpatient clinic of the University Medical Center Groningen, including registration of the patients' clinical and family history, construction of pedigrees and if indicated DNA analysis. Family members at risk are invited for presymptomatic cardiac screening and/or, in those families where a mutation is identified,

presymptomatic DNA analysis. To inform family members at risk, the index patients are asked to distribute letters to their family.¹⁶ DCM is diagnosed using the generally accepted criteria by Mestroni *et al*, that is, reduced systolic function (left ventricular ejection fraction (LVEF) <0.45) and dilation of the left ventricle (LV end-diastolic dimension >117% of the predicted value corrected for body surface area and age) without identifiable causes such as severe hypertension, coronary artery disease and systemic disease.¹⁷ Mild DCM is diagnosed if only one of these criteria is fulfilled. Familial DCM is defined by at least two family members with (mild) DCM or by a patient with DCM with a first-degree relative who died suddenly before the age of 35 years. We reviewed all familial DCM index patients (n=162) and their family members registered at the cardiogenetics outpatient clinic as of 1 January 2012 for the presence of AACM. AACM was defined by patients who developed DCM (without coronary artery disease or other identifiable causes) after treatment with cumulative doses of doxorubicin $\leq$ 450 mg/m² and cumulative doses of epirubicin $\leq$ 600 mg/m² (with or without additional trastuzumab therapy). By using cut-off values that are lower than the generally accepted safety margins of <550 mg/m² for doxorubicin and <900 mg/m² for epirubicin,¹⁰ we aimed to include patients who received at most a submaximal dose of anthracyclines.

Cohort II: Hospital-based registry of adult-onset patients with cancer treated with systemic cancer therapy

Since the late 1980s, the Department of Medical Oncology of the University Medical Center Groningen has routinely collected clinical data on patients with cancer who have been treated with systemic therapy at the University Medical Center Groningen. In this registry, we reviewed all patients (n=6107) for the presence of AACM. AACM was defined by patients diagnosed with a reduced systolic function (LVEF <0.50) after anthracycline treatment, according to the aforementioned cut-off values and after excluding other identifiable causes for LV dysfunction. All patients with AACM who were alive, with no evidence of active malignant disease and with a follow-up of at least 3 years, were informed about the study and asked to complete a questionnaire about their family medical history. Selected patients with AACM who agreed to participate in the study were counselled at our cardiogenetics outpatient clinic (see figure 1 for inclusion criteria). A family history suggestive of DCM was assigned if patients reported one or more relatives with possible heart failure, cardiomyopathy, pacemaker/implantable cardioverter defibrillator (ICD) therapy and/or sudden cardiac death before the age of 60 years (excluding relatives with identifiable causes for cardiac disease or sudden death, such as coronary artery disease).

Patients with an LVEF <0.30 at follow-up, or with a persistent LVEF $\leq$ 0.45 and a first-degree relative with possible cardiomyopathy or myopathy, were offered next

Figure 1 Flow chart patient inclusion. Patients with AACM data were collected from the hospital-based registry of DCM families (cohort I) and two hospital-based registries of patients with cancer (adult- or childhood-onset) treated with systemic cancer therapy (cohort II-adult-onset patients and cohort III-childhood-onset patients). AACM, anthracycline-associated cardiomyopathy; DCM, dilated cardiomyopathy; FU, follow-up; LVEF, left ventricular ejection fraction; SF, shortening fraction; WMSI, wall motion score index.* Two patients from a previously published study.¹³ †Using the cut-off values of ≤ 450 mg/m² for doxorubicin and ≤ 600 mg/m² for epirubicin, we aimed to include patients who received at most the submaximal dose of anthracyclines.

generation DNA sequencing targeting 48 cardiomyopathy-associated genes and cardiological examination of first-degree family members. All other patients were offered limited DNA analysis of four DCM-related genes.

Cohort III: Hospital-based registry of childhood-onset patients with cancer treated with systemic cancer therapy. Between 1976 and 1999, the Division of Pediatric Oncology, Beatrix Children's Hospital, University Medical Center Groningen has collected the clinical data of childhood-onset patients with cancer treated with systemic cancer therapy who survived at least 5 years after diagnosis. As part of a research project on late effects on cardiovascular damage and risk factors, cardiac examinations (including echocardiography) were performed on 277 patients.¹⁵ Using this cohort of 277 patients, we searched for patients with AACM who were treated with a total cumulative dose of doxorubicin ≤ 450 mg/m² and had (1) a wall motion score index (WMSI) ≥ 1.5 and a shortening fraction (SF) < 0.29 , or (2) a WMSI ≥ 1.5 or an SF < 0.29 and a family history suggestive for DCM. All included patients had, apart from their treatment, no other identifiable causes for LV dysfunction. Patients who showed recovery of LV function

without therapy during follow-up (LVEF > 0.55) were excluded. A family history suggestive of DCM was assigned according to the aforementioned criteria (see cohort II). Patients eligible for our study were counselled at our cardiogenetics outpatient clinic and, upon patients' consent, next-generation DNA sequencing targeting 48 cardiomyopathy-associated genes was performed.

Genetic analysis

Blood-derived genomic DNA was obtained from all index patients of DCM families with a patient with AACM (cohort I) and the selected patients with AACM from cohorts II and III. All index patients included in cohort I, cohort III, and all patients with an LVEF < 0.30 at follow-up or with a persistent LVEF ≤ 0.45 and a first-degree relative with possible cardiomyopathy or myopathy from cohort II were screened for mutations in 48 cardiomyopathy-associated genes (*ABCC9*, *ACTC1*, *ACTN2*, *ANKRD1*, *BAG3*, *CALR3*, *CRYAB*, *CSRP3/MLP*, *DES*, *DMD*, *DSC2*, *DSG2*, *DSP*, *EMD*, *GLA*, *JPH2*, *JUP*, *LAMA4*, *LAMP2*, *LMNA*, *MYBPC3*, *MYH6*, *MYH7*, *MYL2*, *MYL3*, *MYPN*, *MYOZ1*, *MYOZ2*, *PKP2*, *PLN*, *PRKAG2*, *PSEN1*, *PSEN2*, *RBM20*, *RYR2*, *SCN5A*, *SGCD*, *TAZ*,

TBX20, *TCAP*, *TMEM4*, *TNNC1*, *TNNI3*, *TNNT2*, *TPM1*, *TTN*, *VCL* and *ZASP/LDB3*) using targeted next-generation DNA sequencing.¹⁸ All novel variations were confirmed by Sanger sequencing. In the remaining index patients from cohort II (n=10), we only analysed the complete coding sequence and intron/exon boundaries of four DCM-related genes (*PLN*, *MYH7*, *LMNA* and *TNNT2*) with Sanger sequencing.¹⁹ Details of these analyses are available on request. Classification of the variants identified was performed according to criteria previously published in van Spaendonck-Zwarts *et al.*¹⁹ Variants were classified as not pathogenic, variant of unknown clinical significance (VUS; VUS1, unlikely to be pathogenic; VUS2, uncertain; VUS3, likely to be pathogenic), or (putative) pathogenic. Co-segregation analysis of VUSs and mutations was performed where possible.

RESULTS

Patient selection and cardiological evaluation

Cohort I: Hospital-based registry of DCM families

Among our hospital-based registry of 162 DCM families, we identified five DCM families with at least one patient with AACM (figure 1). Two of the five families (Id and Ie) had also been identified in the childhood cancer registry (cohort III) and were previously published.¹³ In families Ia and Ib, we identified one patient with AACM and two family members with (mild) DCM. In family Ic, we identified three sisters, two of whom had AACM and one DCM. A fourth sister had died suddenly at the age of 62 years. In family Id, we identified two first-degree relatives (father and brother) of the patient with AACM with (mild) DCM. In family Ie, three relatives (father, brother and paternal uncle) of the patient with AACM had (mild) DCM (table 1 and figure 2).

Cohort II: Hospital-based registry of adult-onset patients with cancer treated with systemic cancer therapy

After applying our selection criteria (figure 1), 43 patients were informed about our study and asked to fill out a questionnaire including questions about family history. Thirteen of these patients were eligible for our study (table 1 (patients IIa through IIn)). Presymptomatic cardiological screening of first-degree relatives was offered to 3/13 patients: patients IIk, IIm, IIIn (table 1). Three daughters of the index patient in family IIk underwent cardiological examination. Two showed no signs of DCM, while one was diagnosed with subnormal LV function (LVEF 0.50). Analysis of the pedigree showed that the brother of patient IIk was diagnosed with a dilated LV with preserved function and atrial fibrillation (AF) (see figure 2). Family members of patient IIm did not respond to our invitation. In family IIIn, cardiological examination of a son of patient IIIn showed no signs of DCM although this patient did have a left bundle branch block, which can be considered a possible precursor of DCM (see figure 2).

Cohort III: Hospital-based registry of childhood-onset patients with cancer treated with systemic cancer therapy
Six patients with AACM of the childhood cancer registry met our selection criteria (figure 1). Of these, one declined to participate and two other patients were already included in cohort I (patients Id and Ie). In family IIIa, we identified a second-degree relative of the index patient who died suddenly at the age of 56 years. In family IIIb, we identified a second-degree relative diagnosed with AF and heart failure. In family IIIc, the father of the index patient was diagnosed with arrhythmia (unspecified) and a cousin of the mother of the index patient had died unexpectedly at the age of 40 years. Detailed clinical data and relevant family data of patients IIIa, IIIb, IIIc are shown in table 1.

Genetic analysis

The genomic DNA of all index patients in DCM families with patients with AACM (cohort I, n=5) and six patients with AACM (n=3 from cohort II and n=3 from cohort III) were screened for mutations in 48 cardiomyopathy-associated genes using next-generation DNA sequencing.¹⁸ Two pathogenic mutations, six VUS1s, and three VUS2s were identified (table 2).

The two pathogenic mutations included a previously reported complex mutation (two missense mutations in *MYH7* on one allele, c.1633G>A (p.Asp545Asn) and c.2863G>A (p.Asp955Asn)) in family Ie^{13 20} and a nonsense mutation (c.4125T>A (p.Tyr1375*)) in *MYH7* in family IIIn. Co-segregation analysis showed that the complex mutation fully segregated with disease in family Ie.¹³ Co-segregation analysis of the nonsense mutation could not be performed, as there was no DNA available from the possibly affected son of the index patient (family IIIn). Sanger sequencing for mutations in the *PLN*, *MYH7*, *LMNA* and *TNNT2* genes in the remaining patients of cohort II (n=10) revealed one VUS2 in family IIc (*MYH7* c.5534G>A, p.Arg1845Gln).

DISCUSSION

This study is the first to systematically investigate the concept that a genetic/familial predisposition for DCM might be a potential risk factor for AACM. In addition to the patients identified in our initial report,¹³ we have identified three new DCM families with patients with AACM (families Ia, Ib and Ic) and revealed previously undiagnosed precursor signs of mild DCM in a first-degree relative of a patient with AACM (family IIIn). Moreover, in two families (Ie and IIIn), we identified pathogenic *MYH7* mutations. These two pathogenic *MYH7* mutations highlight the genetic nature of familial DCM in these families. Yet, this does not prove a causal relation between the identified *MYH7* mutations and the development of AACM in these families, as AACM developed years after anthracycline treatment and other (non-genetic) risk factors might have been involved in AACM development.

Table 1 Characteristics of patients with AACM and their family members

		Treatment		Diagnosis AACM (months after treatment)	LVEF at diagnosis AACM	LVEF at follow-up	Cardiological remarks	Family history		
Pt	Cancer (age at diagnosis)	Tot. cum. dose AC (mg/m ²)	Tot. cum. dose RT in Gy (location)					1st DGRs	2nd DGRs	≥3rd DGRs
Cohort I (n=5)										
Ia	B (49)	450*	50 (R)	9	0.44	Died at age 51 year of sepsis		DCM (54), DCM (53)	Infarct, LVEF 15%	
Ib	B (55)	240†		<1 month	0.41	0.40, after 1 year	CACS: 0	DCM (59)	mild DCM (33)	
Ic	B (49)	450†		168	0.34	unknown	CAG normal	DCM+CABG (57)		
	B (57)	unknown†	unknown	43	unknown	0.42, after 7 months	LBBB	SCD (62)		
Id	ALL (9,12)	175‡	12 (TB)	50	0.24§	0.50, after 16 year		DCM (56), mild DCM (21)	LV+RV dys. (63), SCD (66)	
Ie	N (2)	420*		167	0.15§	0.17, after 14 year	ICD, CAG normal	DCM (57), mild DCM (22)	mild DCM (66), SCD (58)	
Cohort II (n=13)										
IIa	B (58)	455*		3	0.36	0.45, after 5 year		arrhythmia		
IIb	B (46)	432*	50 (L)	63	0.47	0.40–0.45, after 11 year	LBBB, CAG normal		SCD (50)	
IIc	B (47)	332*	46 (L)	21	0.44	0.50–0.55, after 13 year		HF (70)	SCD (40)	SCD (32)
IId	B (38)	360*	50 (L)	14	0.49	0.54, after 14 year				SCD (25–30)
IIe	B (53)	300†	66 (L)	152	0.47	0.55–0.60, after 20 year		arrhythmia (65)		3x SCD (50)
IIf	B (39)	600†	>68 (R,S)	160	0.30–0.40	0.35–0.45, after 16 year	CVA (54), MR grade III		HF (80)	
IIg	BB (34)	450*¶		6	0.47	>0.65, after 6 year		arrhythmia (74)		
IIh	B (50)	450*	166 (L,R,S)	49	0.47	0.60, after 15 year				2x SCD (40 /42)
IIi	B (44)	309†	50 (L)	126	0.46	0.50, after 4 year				
IIj	B (45)	310†	50 (R)	94	0.48	0.43, after 13 year	Tachycardia, MR grade II-III		PM(58)	
IIk	B (60)	450*		3	0.40	0.45, after 5 year	LBBB	AF+dil. LV (63)		

Continued

Table 1 Continued

Pt	Cancer (age at diagnosis)	Treatment		Diagnosis AACM (months after treatment)	LVEF at diagnosis AACM	LVEF at follow-up	Cardiological remarks	Family history		
		Tot. cum. dose AC (mg/m ²)	Tot. cum. dose RT in Gy (location)					1st DGRs	2nd DGRs	≥3rd DGRs
IIIm	B (45)	190†	58 (R)	122	0.45	0.23, after 16 year	ICD, LBBB			
IIIn	B (61)	450*	64 (L)	30	0.40	0.40–0.45, after 5 year	CAG normal	MP (<15), LBBB (43)		
<i>Cohort III (n=3)</i>										
IIIa	W (4)	290*	unknown	12	unknown	0.41, after 35 year	CRT-PM, CAG normal, CVA (35)		SCD (56)	
IIIb	PNET (9)	375†	50 (E)	11	0.25§	0.40–0.45, after 16 year			AF+HF (75)	
IIIc	W (4, 7)	240†		123	0.27§	0.40–0.45, after 19 year		arrhythmia		SCD (40)

Patients Ia, Ib, Ic, Id, Ie and IIIn (indicated in bold) are patients with AACM and familial DCM and/or pathogenic mutation.

AACM, anthracycline-associated cardiomyopathy; AC, anthracyclines; AF, atrial fibrillation; ALL, acute lymphoid leukaemia; B, breast cancer; BB, bilateral breast cancer; CABG, coronary artery bypass graft; CAG, coronary angiography; CACS, coronary artery score; CM, cardiomyopathy; CRT, cardiac resynchronisation therapy; CVA, cerebrovascular accident; DCM, dilated cardiomyopathy; DGRs, degree relative; dil., dilated; E, extremities; HF, heart failure; Gy, gray; ICD, implantable cardioverter defibrillator; L, left thorax; LBBB, left bundle branch block; LV, left ventricle; LVEF, left ventricular ejection fraction; MP, myopathy; MR, mitral regurgitation; N, neuroblastoma; PM, pacemaker; PNET, primary neuroectodermal tumour; Pt, patient; R, right thorax; RT, radiotherapy; RV, right ventricle; S, sternum; SCD, sudden cardiac death; TB, total body; W, Wilms tumour.

*Epirubicin.

†Doxorubicin.

‡Daunorubicin.

§Shortening fraction.

¶Patient treated with trastuzumab.

Figure 2 Pedigrees of patients with AACM and their family members. Square symbols, men; circles, women; diamonds, unknown sex. Blue symbols, patients with AACM; solid black symbols, patients with (mild) DCM; grey symbols, possible DCM; orange symbols, sudden cardiac death. Diagonal lines through symbols, deceased; arrow, index patient; number in a symbol, number of individuals with this symbol.

In the literature, we found two other reports of patients with AACM with a positive family history of cardiomyopathy.^{21 22} Interestingly, one of these families also carried a *MYH7* mutation (*MYH7* c.4276G>A, p. Glu1426Lys). Hence, thus far, *MYH7* mutations have been described in three of eight patients with AACM. Based on these numbers, one might speculate that *MYH7* mutations are more frequent in families with DCM and AACM compared with lone DCM families.¹⁹ However, this finding is likely to be coincidental and also does not, as indicated before, prove a causal relation between the development of AACM and *MYH7* mutation carrier status. Given the large heterogeneity of DCM, it is plausible that genetic analysis of larger numbers of patients with AACM will probably reveal pathogenic mutations in cardiomyopathy-associated genes other than *MYH7*.

In addition to pathogenic *MYH7* mutations, we identified several variants of unknown clinical significance (VUS1s and VUS2s). Based on current knowledge, it is

not clear whether these variants are involved in the pathogenesis of DCM. It is possible that they represent only benign sequence variations. However, it is conceivable that these variants are low-risk or high-risk pathogenic alleles or modifiers. This is especially the case for the VUS2 reported in *VCL* (c.2969C>T, p. Ala990Val) in family Ic. This variant has not been reported before in cardiomyopathy patients or in the 1000 Genomes project. It has been reported at low frequencies in ~6500 exomes of the exome sequencing project (ESP) of the National Heart, Lung, and Blood Institute (NHLBI) (minor allele frequency (MAF) 0,0003) and 1000 Dutch genomes of the GoNL project (MAF 0,003). In addition, the Ala990 amino acid position is highly conserved and several prediction programs classify this amino acid substitution as pathogenic. Moreover, segregation analysis showed that this variant fully segregated with the disease in this family.

Our results support the hypothesis that a genetic/familial predisposition for DCM might be a potential

Table 2 Sequence variants identified through next-generation DNA sequencing of 48 cardiomyopathy-associated genes

Patient	Gene†	Nucleotide change	Predicted protein change	Type of variant
<i>Cohort I</i>				
Ia	<i>DSG2</i>	c.473T>G	p.Val158Gly	VUS1
Ib	<i>JUP</i>	c.1942G>A‡	p.Val648Ile	VUS1
Ic	<i>VCL</i>	c.2969C>T‡	p.Ala990Val	VUS2
Id	–§	–	–	–
Ie	<i>MYH7</i>	c.1633G>A+c.2863G>A‡	p.Asp545Asn+p.Asp955Asn	Pathogenic
	<i>TTN</i>	c.94036_94037delinsCT	p.Ser31346Leu	VUS1
	<i>TTN</i>	c.13358A>G‡	p.Tyr4453Cys	VUS2
<i>Cohort II</i>				
IIk	–§	–	–	–
IIIm	<i>DSP</i>	c.4274G>A	p.Arg1425Lys	VUS1
IIIn	<i>MYH7</i>	c.4125T>A	p.Tyr1375*	Pathogenic
<i>Cohort III</i>				
IIIa	<i>ABCC9</i>	c.2215G>C	p.Pro739Ala	VUS1
IIIb	<i>PKP2</i>	c.1592T>G	p.Ile531Ser	VUS2
	<i>TTN</i>	c.32562_32564dupAGA	p.Glu10855dup	VUS1
IIIc	–‡	–	–	–

VUS indicates variant of unknown clinical significance (VUS1, unlikely to be pathogenic; VUS2, uncertain).

†Nomenclature according to HGVS (Human Genome Variation Society) using the reference sequences: *ABCC9* (NM_005691.2), *DSG2* (NM_001943.3), *DSP* (NM_004415.2), *JUP* (NM_002230.2), *MYH7* (NM_000257.2), *PKP2* (NM_004572.3), *TTN* (NM_001256850.1; Q8WZ42), and *VCL* (NM_014000.2).

‡Co-segregation analysis revealed carriership in all the affected family members.

§No variations identified among 48 cardiomyopathy-associated genes.

risk factor for AACM. The question remains: what is the potential mechanism? A conceivable mechanism could be that genetic inactivation of DCM associated proteins may lower the threshold for the damaging effect of anthracyclines on cardiomyocytes and cardiac function.²³ Depending on reserve and restoration capacity this may result in AACM at a lower threshold.²⁴

Limitations and future research

The descriptive nature of our study design did not enable us to perform statistics on our hypothesis that a genetic predisposition for DCM might be a potential AACM risk factor. Nor did it allow to statistically address the several confounders leading to AACM (such as radiotherapy or coronary artery disease). Also, given that cancer and heart disease are both common diseases of the ageing population,²⁵ it is possible that some included patients developed heart failure independently of anthracycline treatment.²⁶ On the other hand, cardiologic evaluation and cardiac follow-up were not offered to all patients treated with anthracyclines. Since signs of AACM may only become clinically evident several years after anthracycline treatment,^{4 6} it is plausible that we have underestimated the true number of patients with AACM in our study. Further, it is conceivable that some of the patients are carriers of currently unknown pathogenic mutations because, at present, a genetic cause can be found in only ~50% of patients with DCM.^{19 27}

More research is needed to further elucidate the intriguing relationship between a potential genetic predisposition for DCM and AACM. Ideally, this should be multicentre systematic studies including next generation

DNA analysis (gene panel-based and/or exome sequencing) in patients with AACM, and cardiologic screening of first-degree family members. Not only will such studies add to our understanding of the aetiology of AACM and lead to the identification of patients at a high risk for AACM, they may also lead to the identification of novel targets important for the prevention of AACM or even novel cardiomyopathy susceptibility genes.

Conclusion

We have identified five DCM families with one patient with AACM, and one patient with AACM with a family member with a previously unrecognised, possible early sign of mild DCM. In two of these families, we identified pathogenic *MYH7* mutations, confirming the genetic character of the DCM in these families. Although more research is needed, our current data support the hypothesis that a genetic susceptibility for DCM is a potential risk factor for AACM. In view of the reported cases, one should be vigilant for increased susceptibility to AACM if patients report a family history of DCM/heart failure and one may, in these particular cases, consider more intensive cardiovascular monitoring before and during cancer treatment or alternative non-cardiotoxic cancer therapy.

Author affiliations

¹Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

²Department of Clinical Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

³Department of Paediatric Oncology, University Medical Center Groningen, University of Groningen, Beatrix Children's Hospital, Groningen, The Netherlands

⁴Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

⁵Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Acknowledgements We are obliged to all patients who participated in this study. We thank Jackie Senior and Kate McIntyre for editing this manuscript, Nynke Zwart for her help with retrieving data from the childhood cancer registry, and Eddy de Boer, Lennart Johansson and Ludolf Boven for DNA analyses.

Contributors The conception, design, analysis and interpretation of data and drafting of the manuscript were done by MW and KYvS-Z. NLW and JDHJ contributed to the manuscript by analysing and interpreting the data. AP, JAG, JPVt and MPvB provided critical remarks and input to the conception and design of the study. The manuscript was circulated to all the authors for comments. All the authors have seen and approved the final version of the manuscript.

Competing interests None.

Ethics approval Ethical committee of the University Medical Center Groningen.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Meinardi MT, van der Graaf WT, van Veldhuisen DJ, *et al.* Detection of anthracycline-induced cardiotoxicity. *Cancer Treat Rev* 1999;25:237–47.
- Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. *J Am Coll Cardiol* 2009;53:2231–47.
- Chen J, Long JB, Hurria A, *et al.* Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. *J Am Coll Cardiol* 2012;60:2504–12.
- Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. *Heart* 2008;94:525–33.
- Lipshultz SE, Lipsitz SR, Sallan SE, *et al.* Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol* 2005;23:2629–36.
- Steinherz LJ, Steinherz PG, Tan CT, *et al.* Cardiac toxicity 4 to 20 years after completing anthracycline therapy. *JAMA* 1991;266:1672–7.
- Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. *Prog Cardiovasc Dis* 2007;49:330–52.
- Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. *Drug Saf* 2000;22:263–302.
- Zhang S, Liu X, Bawa-Khalife T, *et al.* Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med* 2012;18:1639–42.
- Smith LA, Cornelius VR, Plummer CJ, *et al.* Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. *BMC Cancer* 2010;10:337.
- van Dalen EC, van den Brug M, Caron HN, *et al.* Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. *Eur J Cancer* 2006;42:3199–205.
- Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. *Expert Opin Drug Saf* 2006;5:791–809.
- van den Berg MP, van Spaendonck-Zwarts KY, van Veldhuisen DJ, *et al.* Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity? *Eur J Heart Fail* 2010;12:1297–9.
- van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, *et al.* Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. *Circulation* 2010;121:2169–75.
- Brouwer CA, Postma A, Vonk JM, *et al.* Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. *Eur J Cancer* 2011;47:2453–62.
- van der Roest WP, Pennings JM, Bakker M, *et al.* Family letters are an effective way to inform relatives about inherited cardiac disease. *Am J Med Genet A* 2009;149A:357–63.
- Mestroni L, Maisch B, McKenna WJ, *et al.* Guidelines for the study of familial dilated cardiomyopathies, on behalf of the collaborative research group of the European human and capital mobility project on familial dilated cardiomyopathy. *Eur Heart J* 1999;20:93–102.
- Sikkema-Raddatz B, Johansson LF, de Boer EN, *et al.* Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. *Hum Mutat* 2013;34:1035–42.
- van Spaendonck-Zwarts KY, van Rijsingen IA, van den Berg MP, *et al.* Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience. *Eur J Heart Fail* 2013;15:628–36.
- Hoedemaekers YM, Caliskan K, Majoor-Krakauer D, *et al.* Cardiac beta-myosin heavy chain defects in two families with non-compaction cardiomyopathy: linking non-compaction to hypertrophic, restrictive, and dilated cardiomyopathies. *Eur Heart J* 2007;28:2732–7.
- Shipman KE, Arnold I. Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy. *J Clin Oncol* 2011;29:e537–8.
- Young AC, Mercer B, Perren TJ, *et al.* Anthracycline-induced cardiomyopathy in siblings with early breast cancer. *Ann Oncol* 2011;22:1692.
- Octavia Y, Tocchetti CG, Gabrielson KL, *et al.* Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol* 2012;52:1213–25.
- Khouri MG, Douglas PS, Mackey JR, *et al.* Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. *Circulation* 2012;126:2749–63.
- Albini A, Pennesi G, Donatelli F, *et al.* Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. *J Natl Cancer Inst* 2010;102:14–25.
- Lindenfeld J, Kelly PA. Developing a cardiology–oncology clinical practice guideline. *Prog Cardiovasc Dis* 2010;53:173–9.
- Herman DS, Lam L, Taylor MR, *et al.* Truncations of titin causing dilated cardiomyopathy. *N Engl J Med* 2012;366:619–28.